Dendritic Cells as Carriers for a Cytotoxic T-Lymphocyte Epitope-Based Peptide Vaccine in Protection Against a Human Papillomavirus Type 16-Induced Tumor
Miriam A. Ossevoort, W. Martin Kast(University of Southern California), Mariet C.W. Feltkamp(Leiden University Medical Center), Karin J. H. van Veen(Leiden University), Cornelis J.M. Melief(ISA Pharmaceuticals (Netherlands))
Cited by 131
Related Papers
Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity
|Nature Medicine|1995|1.1k
The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes.
|The Journal of Immunology|1994|851
Vaccination with cytotoxic T lymphocyte epitope‐containing peptide protects against a tumor induced by human papillomavirus type 16‐transformed cells
|European Journal of Immunology|1993|840
Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells
|Nature Medicine|2002|549
Mechanism of Immune Dysfunction in Cancer Mediated by Immature Gr-1+ Myeloid Cells
|The Journal of Immunology|2001|533